Cadenceneuro

Cadence Neuroscience operates at the intersection of implantable neuromodulation, epilepsy care, and biomarker-guided therapy. Its initial focus is focal drug-resistant epilepsy, a clinically demanding segment where treatment response can vary substantially between patients. The company differentiates its approach from conventional stimulation protocols by combining continuous brain-activity recording, Artifact Reduction Technology, patient-specific EEG biomarkers, and Biomarker Targeted Stimulation. This creates a feedback-oriented model intended to show how neural circuits respond during therapy rather than relying solely on generalized programming settings. Cadence’s platform originated from neuroscience work at Mayo Clinic and is under clinical evaluation, placing it closer to a clinical-stage medical-device company than to a software-only digital-health provider. Its $41.03 million in structured funding, six-to-50-person employee band, and 2023 Series B indicate meaningful venture backing while still reflecting an early-stage development profile.

Cadence Neuroscience was established in 2017 and raised a $15 million Series A on Oct 11, 2019, alongside a recorded grant. The company then reached a $26.03 million Series B on Feb 28, 2023, increasing cumulative structured funding to $41.03 million and marking its latest financing event. Its core inflection point is the transition from developing a neuromodulation concept to evaluating a platform that can continuously record brain activity for up to 32 hours across multiple electrode targets and use patient-specific biomarkers to guide stimulation. Hiring signals indicate growth to more than 30 employees and contractors, with continued demand for clinical and research staff. Leadership changes reinforce the next phase: Daniel Moore joined the board in December 2025, and Chris Cronin became CEO on Sep 22, 2026. These appointments suggest increasing emphasis on clinical operations, regulatory progress, and eventual commercialization, but the timing of market launch remains undisclosed.